AGP Executive Report
Last update: 9 hours agoEU Drug Approvals: CinnaGen became the first Iranian pharma to win European Commission approval for its osteoporosis medicine Zandoriah (teriparatide), following EMA CHMP positive opinions and strict EU GMP checks. Cancer Care in Europe: The European Commission also approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in patients aged 12+. Health Tech in the Region: Fi expanded its AI-powered GPS pet wearables to 38 countries, adding coverage across parts of North America and Europe and including Switzerland, Norway, and Liechtenstein. Heat & Safety: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, with warnings that more incidents may follow. Travel Health Access (UK): UK guidance highlights that travellers should apply for a free GHIC card before trips to help access state healthcare abroad, but it doesn’t replace travel insurance. Local Relevance: For Liechtenstein readers, the big health angle is EU approvals and regional access for new therapies and health-related tech.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
